ChitogenX Inc. (CHNXF)
USD 0.01
(-13.38%)
USD 0.01
(-13.38%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 712 Thousand CAD | -85.27% |
| 2023 | 4.83 Million CAD | 40.41% |
| 2022 | 3.44 Million CAD | 15.85% |
| 2021 | 2.97 Million CAD | 31.23% |
| 2020 | 2.26 Million CAD | -8.57% |
| 2019 | 2.47 Million CAD | 23.91% |
| 2018 | 1.99 Million CAD | 8.56% |
| 2017 | 1.84 Million CAD | 177.92% |
| 2016 | 662.34 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 380 Thousand CAD | -37.81% |
| 2024 Q1 | 1.46 Million CAD | 23.52% |
| 2024 Q4 | 734 Thousand CAD | 93.16% |
| 2024 FY | 2.78 Million CAD | -42.31% |
| 2024 Q2 | 611 Thousand CAD | -58.29% |
| 2023 Q4 | 1.18 Million CAD | -1.0% |
| 2023 Q1 | 1.25 Million CAD | 37.68% |
| 2023 Q2 | 1.11 Million CAD | -11.22% |
| 2023 FY | 4.83 Million CAD | 40.41% |
| 2023 Q3 | 1.19 Million CAD | 7.35% |
| 2022 Q3 | 991 Thousand CAD | 73.25% |
| 2022 FY | 3.44 Million CAD | 15.85% |
| 2022 Q4 | 913 Thousand CAD | -7.87% |
| 2022 Q2 | 572 Thousand CAD | -37.89% |
| 2022 Q1 | 921 Thousand CAD | -5.44% |
| 2021 Q3 | 634 Thousand CAD | 47.44% |
| 2021 Q2 | 430 Thousand CAD | -51.79% |
| 2021 Q1 | 892 Thousand CAD | 154.86% |
| 2021 Q4 | 974 Thousand CAD | 53.63% |
| 2021 FY | 2.97 Million CAD | 31.23% |
| 2020 Q2 | 562 Thousand CAD | 2.55% |
| 2020 Q3 | 711 Thousand CAD | 26.51% |
| 2020 Q4 | 350 Thousand CAD | -50.77% |
| 2020 FY | 2.26 Million CAD | -8.57% |
| 2020 Q1 | 548 Thousand CAD | -22.14% |
| 2019 Q3 | 749 Thousand CAD | 67.94% |
| 2019 Q1 | 407 Thousand CAD | -29.3% |
| 2019 Q2 | 446 Thousand CAD | 9.58% |
| 2019 Q4 | 703.81 Thousand CAD | -6.03% |
| 2019 FY | 2.47 Million CAD | 23.91% |
| 2018 Q3 | 596.1 Thousand CAD | 55.7% |
| 2018 Q2 | 382.84 Thousand CAD | 64.43% |
| 2018 Q1 | 232.83 Thousand CAD | 43.09% |
| 2018 Q4 | 575.68 Thousand CAD | -3.43% |
| 2018 FY | 1.99 Million CAD | 8.56% |
| 2017 Q2 | 539.05 Thousand CAD | 99.47% |
| 2017 Q4 | 162.71 Thousand CAD | -64.84% |
| 2017 FY | 1.84 Million CAD | 177.92% |
| 2017 Q1 | 270.24 Thousand CAD | -33.36% |
| 2017 Q3 | 462.82 Thousand CAD | -14.14% |
| 2016 FY | 662.34 Thousand CAD | 0.0% |
| 2016 Q1 | 36.53 Thousand CAD | 0.0% |
| 2016 Q2 | 53.58 Thousand CAD | 46.68% |
| 2016 Q3 | 166.68 Thousand CAD | 211.07% |
| 2016 Q4 | 405.54 Thousand CAD | 143.3% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | 80.497% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 46.927% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 72.902% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 97.591% |
| GB Sciences, Inc. | 1.42 Million USD | 49.877% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 79.089% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -223.522% |
| Skye Bioscience, Inc. | 13.54 Million USD | 94.744% |
| Zenith Capital Corp. | 8.94 Million USD | 92.038% |
| Agentix Corp. | 1.37 Million USD | 48.096% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 85.879% |
| Biomind Labs Inc. | 994.18 Thousand USD | 28.383% |
| ContraFect Corporation | 56.88 Million USD | 98.748% |
| CSL Limited | 3.44 Billion USD | 99.979% |
| CytoDyn Inc. | 18.05 Million USD | 96.057% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 61.81% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -82.767% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.76% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -71.368% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 52.593% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 22.903% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 98.089% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.168% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 65.246% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.18% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 75.585% |
| Mesoblast Limited | 5.9 Million USD | 87.936% |
| Marizyme, Inc. | 19.23 Million USD | 96.299% |
| Genus plc | 147.7 Million USD | 99.518% |
| Pharming Group N.V. | 225.49 Million USD | 99.684% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 91.462% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 51.851% |
| IMV Inc. | 37.7 Million USD | 98.112% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 74.484% |
| MultiCell Technologies, Inc. | 567.42 USD | -125380.244% |
| ONE Bio Corp. | 6.44 Million USD | 88.951% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.172% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 97.119% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 59.538% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 89.402% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 2948.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 95.553% |
| Alpha Cognition Inc. | 9.7 Million USD | 92.664% |
| Enzolytics Inc. | 2.17 Million USD | 67.332% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.954% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 31.801% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 70.394% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.914% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 85.522% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -172.04% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 71.002% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -315.139% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 62.934% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 91.89% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 83.85% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | 80.995% |
| Helix BioMedix, Inc. | 1.97 Million USD | 63.895% |
| EV Biologics, Inc. | 531.96 Thousand USD | -33.844% |
| Q BioMed Inc. | 3.43 Million USD | 79.282% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 93.448% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.283% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 96.901% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 61.201% |
| HST Global, Inc. | 140.9 Thousand USD | -405.298% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 46.684% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 36.706% |
| Halberd Corporation | 74.84 Thousand USD | -851.337% |
| Resverlogix Corp. | 12.71 Million USD | 94.399% |
| Cell Source, Inc. | 4.32 Million USD | 83.539% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 54.918% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | 90.26% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -3987.021% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | 71.136% |
| Kadimastem Ltd | 2.41 Million USD | 70.458% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 83.201% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -292.319% |
| LadRx Corporation | 3.81 Million USD | 81.321% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 22.903% |
| Affymax, Inc. | 39.38 Million USD | 98.192% |
| Itoco Inc. | 919.14 Thousand USD | 22.537% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 36.372% |
| Mobile Lads Corp. | 554.54 Thousand USD | -28.393% |
| International Stem Cell Corporation | 5.27 Million USD | 86.492% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | 81.362% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -2728.877% |
| Qrons Inc. | 643.67 Thousand USD | -10.614% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 49.852% |
| SYBLEU INC | 160.87 Thousand USD | -342.577% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 68.07% |
| Rebus Holdings, Inc. | 664 Thousand USD | -7.229% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 60.8% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1252.532% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -3399.975% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 98.037% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 55.995% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 3.239% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 77.113% |
| Neutra Corp. | 243.82 Thousand USD | -192.018% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 95.921% |
| PureTech Health plc | 144.59 Million USD | 99.508% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 96.525% |
| IXICO plc | 4.7 Million USD | 84.874% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 91.906% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.395% |
| CSL Limited | 3.89 Billion USD | 99.982% |
| Cellectis S.A. | 97.32 Million USD | 99.268% |